ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Translate Bio taps AMRI to make mRNA

by Michael McCoy
October 5, 2019 | APPEARED IN VOLUME 97, ISSUE 39

 

The messenger RNA drug company Translate Bio has picked Albany Molecular Research Inc. (AMRI), a pharmaceutical services firm, to manufacture mRNA for drugs in clinical trials. Under the 5-year agreement, AMRI will build clinical manufacturing suites dedicated to Translate Bio. The biotech firm’s lead mRNA drug is an inhaled treatment for cystic fibrosis now in a Phase I/II trial.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment